March 24, 2026
Rx Pricing: MFN “Deals” & Legal Landmines
Our review of comment submissions for CMS’s most favored nation (MFN) drug pricing model proposals in Medicare Part D (GUARD) and B (GLOBE) leave us with just ~30% odds of their being implemented. The risk…
February 28, 2025
R&D Tax Credit: Companies Likely to Get a Boost
We continue to believe that full expensing / deductibility of the R&D tax credit in the year expenses occur will be part of the massive reconciliation / tax bill we expect to see enacted in…